Novo Nordisk and AI-driven protein design company Gensaic are to develop tissue-targeted therapies for cardiometabolic ...

As the field of regenerative medicine continues to advance, the incorporation of AI is playing a transformative role in the ...

The EC has authorised the marketing of Bavarian Nordic's Vimkunya chikungunya vaccine for individuals as young as 12 years ...

Regenerative medicine, a rapidly advancing field, can be generally defined as a therapeutic methodology for the repair, ...

BridgeBio Oncology has entered into a merger agreement with Helix Acquisition Corp II to form a combined entity.

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire rights to a long-acting amylin ...

Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly for molecular glue therapeutics.

Avtozma is the 12th biosimilar from Celltrion to receive approval from the EC. Credit: © CELLTRION INC. All Rights Reserved.

As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...

Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...

The company's IPO follows a $182m Series C funding round last year.

Genitourinary Cancer Symposium 2025, held on 13-15 February, final results from the randomised, multicentre, double-blind, ...